$TVGN

Tevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 2, 2026, Susan Podlogar gave notice of her resignation from service as a director of Tevogen Inc. (the “Company

Tevogen amended its loan agreement with The Patel Family, extending borrowing availability through 2029 with up to $28.6 million remaining. The amendment sets a $7.40-per-share price for stock repayment and adjusts share issuance terms. Tevogen repaid its existing $7.4 million principal and $177,880 interest in shares on November 2, 2026.

Tevogen granted CEO Ryan Saadi 50 million restricted shares, vesting contingent on $1 billion in revenue by 2031. The award aims to align his interests with the company's long-term growth. According to the SEC filing, unvested shares are forfeited if conditions aren't met or if Saadi leaves the company.

Tevogen Inc. (TVGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 27, 2026 (the “First Amendment Effective Date”), Tevogen Inc. (the “Company”) entered into the First Amendment to Loan Agreement (the “Amendment”) with The Patel Family, LLP (the “Lender”), amending the Loan Agreeme

Tevogen Inc. (TVGN) signed a non-binding LOI to evaluate acquiring HRK Healthcare LLC, potentially expanding its healthcare services and targeting $100M in combined annual revenue if completed. The deal is in early stages, with no definitive agreement or terms disclosed yet, according to the company.

Tevogen Bio Holdings has regained compliance with Nasdaq's minimum market value requirement. The company's stock has seen a 5-day change of 6.620 USD, a 1st Jan change of -1.93%, and a year-to-date change of -60.01%.

Tevogen Inc. (TVGN) announced it has regained compliance with Nasdaq's $50 million minimum market value requirement for listed securities, closing related compliance matters. The company previously met another compliance requirement on September 9, 2026.

Tevogen Inc. (TVGN) announced it has regained compliance with Nasdaq's $50M minimum market value requirement. The company previously met the minimum public float rule, closing related compliance matters. Tevogen focuses on healthcare, biotech, AI, and services to improve medicine affordability and access.

Tevogen Inc. (TVGN) reports Ryan H. Saadi now owns 74.4% of its shares, including 9.77M restricted shares. The company granted Saadi 8M additional restricted shares, vesting only if TVGN achieves $1B in revenue by 2031.

Tevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Restricted Stock Awards On September 14, 2026 (the “Grant Date”), Tevogen Inc. (the “Company”) granted the Company’s execut